Protagonist Therapeutics, Inc PTGX
Analyst Ratings
- Consensus
- Buy — 14 Buy · 0 Hold · 0 Sell (14 analysts)
- Avg. Price Target
- $144.29 (+2.4% upside)
Key Stats
- Today's Range
- $140.63 – $143.69
- 50-Day Range
- $130.63 – $160.81
- 52-Week Range
- $54.50 – $160.81
- Volume
- 143K shs
- Average Volume
- 602K shs
- Market Cap
- $9.18 billion
- P/E Ratio
- 138.14
- Dividend Yield
- —
Valuation
- P/E Ratio
- 138.14
- Price / Book
- 10.91
- Price / Sales
- 32.55
Short Interest
- Short Interest
- 0.62%
- Days to Cover
- 3.89
Financials (TTM)
- Revenue
- $281.99 million
- Net Income
- $82.91 million
- Net Margin
- 29.40%
- Return on Equity
- 9.85%
- Debt-to-Equity
- —
About Protagonist Therapeutics, Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Related Stocks
Compare head-to-head: PTGX vs LLY·PTGX vs JNJ·PTGX vs ABBV·PTGX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.